Overview of cancer patient perspectives on cannabis use during treatment.

Kathy J Helzlsouer, Sonia M Rosenfield, Andrew N Freedman, Gary L Ellison
{"title":"Overview of cancer patient perspectives on cannabis use during treatment.","authors":"Kathy J Helzlsouer, Sonia M Rosenfield, Andrew N Freedman, Gary L Ellison","doi":"10.1093/jncimonographs/lgae025","DOIUrl":null,"url":null,"abstract":"<p><p>Expanding legal access to medical cannabis across the United States increases availability and use of cannabis products to manage cancer-related symptoms and treatment side effects despite the lack of research-based evidence on its potential benefits and harms. To address knowledge gaps in how cancer patients access and use cannabis, their perceived risks and benefits with its use, and whether cancer patients discuss cannabis use with their healthcare providers during treatment, the National Cancer Institute (NCI) supported 12 NCI-designated comprehensive cancer centers to conduct surveys, which included NCI standardized core questions on cannabis use during treatment, among their cancer patient populations. This overview highlights key results from the articles contained in the monograph, which includes a summary of the results of core questions across all centers and reports from individual or groups of cancer centers on survey results related to the sourcing of cannabis, associated cost, behavioral factors associated with cannabis use (such as smoking, drinking, or using other substances), patient-provider communication on cannabis use during treatment, ethnic variations in patterns, sources, and reasons for cannabis use as well as methodologic concerns related to survey data analysis. The results of these surveys of cannabis use after the diagnosis of cancer lay the groundwork for much-needed research to answer the questions of benefits and harms, including potential interactions with cancer treatments for cancer patients.</p>","PeriodicalId":73988,"journal":{"name":"Journal of the National Cancer Institute. Monographs","volume":"2024 66","pages":"199-201"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303853/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute. Monographs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncimonographs/lgae025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Expanding legal access to medical cannabis across the United States increases availability and use of cannabis products to manage cancer-related symptoms and treatment side effects despite the lack of research-based evidence on its potential benefits and harms. To address knowledge gaps in how cancer patients access and use cannabis, their perceived risks and benefits with its use, and whether cancer patients discuss cannabis use with their healthcare providers during treatment, the National Cancer Institute (NCI) supported 12 NCI-designated comprehensive cancer centers to conduct surveys, which included NCI standardized core questions on cannabis use during treatment, among their cancer patient populations. This overview highlights key results from the articles contained in the monograph, which includes a summary of the results of core questions across all centers and reports from individual or groups of cancer centers on survey results related to the sourcing of cannabis, associated cost, behavioral factors associated with cannabis use (such as smoking, drinking, or using other substances), patient-provider communication on cannabis use during treatment, ethnic variations in patterns, sources, and reasons for cannabis use as well as methodologic concerns related to survey data analysis. The results of these surveys of cannabis use after the diagnosis of cancer lay the groundwork for much-needed research to answer the questions of benefits and harms, including potential interactions with cancer treatments for cancer patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症患者对治疗期间使用大麻的看法概览。
尽管缺乏有关大麻潜在益处和危害的研究证据,但在美国各地扩大医用大麻的合法使用范围,增加了大麻产品的供应和使用,以控制癌症相关症状和治疗副作用。为了解决癌症患者如何获取和使用大麻、他们对使用大麻的风险和益处的认识、以及癌症患者在治疗期间是否与他们的医疗服务提供者讨论大麻使用情况等方面的知识差距,美国国家癌症研究所(NCI)支持 12 个 NCI 指定的综合癌症中心在其癌症患者群体中开展调查,其中包括 NCI 关于治疗期间大麻使用情况的标准化核心问题。本概述重点介绍了专著所载文章中的主要结果,其中包括所有中心核心问题的结果摘要,以及个别癌症中心或癌症中心小组关于以下方面调查结果的报告:大麻来源、相关费用、与使用大麻有关的行为因素(如吸烟、饮酒或使用其他物质)、治疗期间患者与提供方就使用大麻问题进行的沟通、使用大麻的模式、来源和原因方面的种族差异以及与调查数据分析有关的方法学问题。这些关于癌症确诊后使用大麻情况的调查结果为亟需开展的研究奠定了基础,以便回答癌症患者使用大麻的益处和害处问题,包括与癌症治疗可能产生的相互作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
0
期刊最新文献
Challenges to and considerations of designing cancer prevention trials. Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials. Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST). Global perspectives on patient-centered outcomes: advancing patient-centered cancer clinical trials globally. Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1